Characteristics of patients with grade 4 bleeding
Cohort . | Patient ID . | Induction treatment . | Age at induction . | Sex . | WHO bleeding location . | Bleeding onset (days) . | WBC . | Platelets . | PT-INR . | PTT . | D-dimer . | ISTH-DIC criteria . | Grade 4Bleeding risk . | ISTH-DIC score . | Grade 4 Bleeding score . | Total bilirubin . | Albumin . | LDH* . | Alive at day+60 . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D | 7 | Cytarabine (200) + Daunorubicin (60) | 60 | F | CNS | 9 | 2.6 | 29 | 1.6 | 43.7 | >4000 | Positive | High | 7 | 3 | 0.5 | 2.4 | 1174 | No |
D | 18 | Cytarabine (200) + Daunorubicin (60) | 68 | M | CNS gastrointestinal | 5 | 166.4 | 79 | 2.2 | 42.1 | High | 2 | 0.6 | 3.1 | 2151 | No | |||
D | 40 | CPX-351 | 63 | F | CNS (retinal with symptoms) | 19 | 18.2 | 34 | 1.6 | 3786 | Positive | High | 6 | 3 | 1.2 | 3.5 | 684 | Yes | |
D | 41 | Cytarabine (200) + Daunorubicin (60) | 72 | M | CNS | 3 | 17.4 | 42 | 1.4 | 41.0 | Low | 1 | 0.4 | 3.5 | 467 | Yes | |||
D | 62 | Cytarabine (200) + Daunorubicin (60) | 56 | F | CNS | 14 | 16.3 | 5 | 1.5 | 34.9 | High | 2 | 1.5 | 2.8 | 1699 | No | |||
D | 99 | Cytarabine (200) + Daunorubicin (60) | 54 | F | CNS | -14 | 6.4 | 25 | 1.4 | 44.9 | High | 2 | 0.5 | 2.4 | 372 | Yes | |||
D | 100 | Cytarabine (100) + Daunorubicin (90) | 58 | F | CNS | 17 | 12.9 | 98 | 1.4 | 48.3 | >4000 | Positive | Low | 5 | 1 | 0.6 | 2.8 | 850 | No |
D | 121 | Cytarabine (100) + Daunorubicin (90) | 55 | F | CNS | 19 | 5.5 | 8 | 1.4 | 63.3 | High | 2 | 0.6 | 3.4 | 803 | Yes | |||
D | 130 | Cytarabine (100) + Daunorubicin (90) | 45 | F | CNS (retinal with symptoms) | 0 | 37.4 | 10 | 1.6 | 43.5 | >4000 | Positive | High | 7 | 3 | 0.8 | 3.5 | 647 | Yes |
D | 139 | Cytarabine (200) + Daunorubicin (45) | 27 | M | CNS (retinal with symptoms) pulmonary | -5 | 232.7 | 22 | 1.5 | 36.1 | >4000 | Positive | High | 6 | 3 | 1.4 | 3.0 | 806 | No |
D | 166 | Cytarabine (100) + Daunorubicin (90) | 23 | F | CNS (retinal with symptoms) | 14 | 12.1 | 33 | 1.5 | 33.0 | 1158 | Positive | High | 5 | 2 | 0.5 | 3.5 | 309 | Yes |
D | 176 | Cytarabine (200) + Daunorubicin (60) | 61 | M | CNS | 13 | 28.9 | 34 | 1.6 | 61.1 | >4000 | Positive | High | 7 | 3 | 2.2 | 2.7 | 2501 | No |
D | 190 | Cytarabine (100) + Daunorubicin (90) | 30 | F | CNS | 13 | 16.3 | 21 | 1.5 | 34.7 | >4000 | Positive | High | 6 | 2 | 0.4 | 2.8 | 751 | No |
D | 195 | Cytarabine (100) + Daunorubicin (90) | 55 | M | CNS (retinal with symptoms) | -4 | 90.9 | 16 | 1.2 | 29.4 | >4000 | Positive | Low | 5 | 1 | 0.8 | 3.7 | 2255 | Yes |
D | 237 | CPX-351 | 67 | M | CNS | 19 | 1.3 | 192 | 1.2 | 37.0 | Low | 0 | 149 | Yes | |||||
D | 240 | Cytarabine (200) + Daunorubicin (45) | 54 | M | Body cavity | 60 | 0.8 | 27 | 1.2 | Low | 1 | 0.9 | 3.7 | 163 | Yes | ||||
D | 251 | Cytarabine (200) + Daunorubicin (60) | 30 | F | CNS | 7 | 30.8 | 40 | 1.1 | 27.2 | Low | 1 | 0.2 | 3.8 | 439 | No | |||
D | 268 | Cytarabine (200) + Daunorubicin (60) | 56 | M | CNS | 15 | 6.1 | 32 | 1.1 | 37.7 | Low | 1 | 0.4 | 4.4 | 473 | Yes | |||
D | 280 | Cytarabine (100) + Daunorubicin (90) | 39 | F | Pulmonary | 0 | 38.8 | 28 | 1.7 | 41.5 | High | 3 | 0.5 | 3.5 | 1836 | No | |||
D | 336 | CPX-351 | 66 | M | Body cavity | 18 | 107.3 | 50 | 2.1 | 47.4 | High | 2 | 0.9 | 2.1 | 588 | No | |||
V | 10 | 3 + 7 | 22 | M | CNS (retinal with symptoms) | 14 | 19.2 | 147 | 1.1 | 30.6 | 706 | Negative | Low | 2 | 0 | 0.3 | 3.9 | 1066 | Yes |
V | 26 | 3 + 7 | 55 | F | CNS | 8 | 67.5 | 84 | 1.8 | 25.0 | >20 000† | Positive | High | 6 | 2 | 0.1 | 3.6 | 2338 | Yes |
V | 30 | 3 + 7 | 40 | M | CNS | -3 | 18.3 | 7 | 2.4 | 28.9 | >20 000† | Positive | High | 7 | 3 | 2.3 | 3.3 | 22084 | Yes |
V | 58 | 3 + 7 | 55 | M | CNS | 21 | 41.4 | 58 | 1.3 | 30.0 | >20 000† | Positive | Low | 5 | 0 | 0.7 | 3.6 | 4489 | Yes |
V | 97 | 3 + 7 | 65 | M | CNS | 35 | 109.8 | 156 | 1.1 | 27.5 | 1720 | Negative | Low | 2 | 0 | 0.5 | 4.8 | 2063 | Yes |
V | 117 | 3 + 7 | 68 | F | Musculoskeletal | 47 | 166.4 | 47 | 1.6 | 51.8 | High | 2 | 0.6 | 3.4 | 2502 | No | |||
V | 121 | 3 + 7 | 69 | M | CNS | 25 | 41.6 | 24 | 1.4 | 34.3 | High | 2 | 1.2 | 2.7 | 1135 | No | |||
V | 124 | 3 + 7 | 79 | M | Gastrointestinal | 48 | 56.2 | 40 | 1.1 | 35.8 | 2370 | Negative | Low | 4 | 1 | 0.6 | 3.0 | 754 | Yes |
V | 127 | 3 + 7 | 69 | F | CNS | 11 | 12.2 | 49 | 1.9 | 45.1 | >20 000 | Positive | High | 8 | 2 | 0.6 | 4.4 | 13927 | Yes |
V | 130 | 3 + 7 | 67 | M | CNS (retinal with symptoms) | 4 | 0.6 | 23 | 1.4 | 43.4 | 1960 | Positive | High | 5 | 2 | 1.3 | 2.9 | 988 | Yes |
V | 135 | 3 + 7 | 69 | F | CNS | -2 | 8.0 | 5 | 1.3 | 35.8 | Low | 1 | 1.0 | 3.3 | 842 | No | |||
V | 142 | 3 + 7 | 67 | F | Gastrointestinal | 6 | 23.0 | 321 | 1.2 | 33.7 | Low | 0 | 0.4 | 2.9 | 675 | Yes | |||
V | 148 | 3 + 7 | 68 | M | CNS (retinal with symptoms) | 13 | 0.8 | 105 | 1.1 | 36.8 | 2350 | Negative | Low | 2 | 0 | 0.5 | 3.8 | 342 | Yes |
V | 160 | 3 + 7 | 74 | F | CNS | 29 | 6.2 | 66 | 1.2 | 49.5 | 3830 | Negative | Low | 4 | 1 | 1.2 | 3.6 | 1359 | Yes |
Summary statistics per cohort | |||||||||||||||||||
Median | % M | % CNS | Median | Median | Median | Median | Median | Median | Median | Median | Median | % Alive | |||||||
D | 55 | 45 | 85 | 13 | 16.9 | 31 | 1.5 | 41.3 | 2472 | 0.6 | 3.4 | * | 50 | ||||||
V | 68 | 57 | 79 | 14 | 21.1 | 54 | 1.3 | 35.1 | 2155 | 0.6 | 3.5 | * | 79 |
Cohort . | Patient ID . | Induction treatment . | Age at induction . | Sex . | WHO bleeding location . | Bleeding onset (days) . | WBC . | Platelets . | PT-INR . | PTT . | D-dimer . | ISTH-DIC criteria . | Grade 4Bleeding risk . | ISTH-DIC score . | Grade 4 Bleeding score . | Total bilirubin . | Albumin . | LDH* . | Alive at day+60 . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D | 7 | Cytarabine (200) + Daunorubicin (60) | 60 | F | CNS | 9 | 2.6 | 29 | 1.6 | 43.7 | >4000 | Positive | High | 7 | 3 | 0.5 | 2.4 | 1174 | No |
D | 18 | Cytarabine (200) + Daunorubicin (60) | 68 | M | CNS gastrointestinal | 5 | 166.4 | 79 | 2.2 | 42.1 | High | 2 | 0.6 | 3.1 | 2151 | No | |||
D | 40 | CPX-351 | 63 | F | CNS (retinal with symptoms) | 19 | 18.2 | 34 | 1.6 | 3786 | Positive | High | 6 | 3 | 1.2 | 3.5 | 684 | Yes | |
D | 41 | Cytarabine (200) + Daunorubicin (60) | 72 | M | CNS | 3 | 17.4 | 42 | 1.4 | 41.0 | Low | 1 | 0.4 | 3.5 | 467 | Yes | |||
D | 62 | Cytarabine (200) + Daunorubicin (60) | 56 | F | CNS | 14 | 16.3 | 5 | 1.5 | 34.9 | High | 2 | 1.5 | 2.8 | 1699 | No | |||
D | 99 | Cytarabine (200) + Daunorubicin (60) | 54 | F | CNS | -14 | 6.4 | 25 | 1.4 | 44.9 | High | 2 | 0.5 | 2.4 | 372 | Yes | |||
D | 100 | Cytarabine (100) + Daunorubicin (90) | 58 | F | CNS | 17 | 12.9 | 98 | 1.4 | 48.3 | >4000 | Positive | Low | 5 | 1 | 0.6 | 2.8 | 850 | No |
D | 121 | Cytarabine (100) + Daunorubicin (90) | 55 | F | CNS | 19 | 5.5 | 8 | 1.4 | 63.3 | High | 2 | 0.6 | 3.4 | 803 | Yes | |||
D | 130 | Cytarabine (100) + Daunorubicin (90) | 45 | F | CNS (retinal with symptoms) | 0 | 37.4 | 10 | 1.6 | 43.5 | >4000 | Positive | High | 7 | 3 | 0.8 | 3.5 | 647 | Yes |
D | 139 | Cytarabine (200) + Daunorubicin (45) | 27 | M | CNS (retinal with symptoms) pulmonary | -5 | 232.7 | 22 | 1.5 | 36.1 | >4000 | Positive | High | 6 | 3 | 1.4 | 3.0 | 806 | No |
D | 166 | Cytarabine (100) + Daunorubicin (90) | 23 | F | CNS (retinal with symptoms) | 14 | 12.1 | 33 | 1.5 | 33.0 | 1158 | Positive | High | 5 | 2 | 0.5 | 3.5 | 309 | Yes |
D | 176 | Cytarabine (200) + Daunorubicin (60) | 61 | M | CNS | 13 | 28.9 | 34 | 1.6 | 61.1 | >4000 | Positive | High | 7 | 3 | 2.2 | 2.7 | 2501 | No |
D | 190 | Cytarabine (100) + Daunorubicin (90) | 30 | F | CNS | 13 | 16.3 | 21 | 1.5 | 34.7 | >4000 | Positive | High | 6 | 2 | 0.4 | 2.8 | 751 | No |
D | 195 | Cytarabine (100) + Daunorubicin (90) | 55 | M | CNS (retinal with symptoms) | -4 | 90.9 | 16 | 1.2 | 29.4 | >4000 | Positive | Low | 5 | 1 | 0.8 | 3.7 | 2255 | Yes |
D | 237 | CPX-351 | 67 | M | CNS | 19 | 1.3 | 192 | 1.2 | 37.0 | Low | 0 | 149 | Yes | |||||
D | 240 | Cytarabine (200) + Daunorubicin (45) | 54 | M | Body cavity | 60 | 0.8 | 27 | 1.2 | Low | 1 | 0.9 | 3.7 | 163 | Yes | ||||
D | 251 | Cytarabine (200) + Daunorubicin (60) | 30 | F | CNS | 7 | 30.8 | 40 | 1.1 | 27.2 | Low | 1 | 0.2 | 3.8 | 439 | No | |||
D | 268 | Cytarabine (200) + Daunorubicin (60) | 56 | M | CNS | 15 | 6.1 | 32 | 1.1 | 37.7 | Low | 1 | 0.4 | 4.4 | 473 | Yes | |||
D | 280 | Cytarabine (100) + Daunorubicin (90) | 39 | F | Pulmonary | 0 | 38.8 | 28 | 1.7 | 41.5 | High | 3 | 0.5 | 3.5 | 1836 | No | |||
D | 336 | CPX-351 | 66 | M | Body cavity | 18 | 107.3 | 50 | 2.1 | 47.4 | High | 2 | 0.9 | 2.1 | 588 | No | |||
V | 10 | 3 + 7 | 22 | M | CNS (retinal with symptoms) | 14 | 19.2 | 147 | 1.1 | 30.6 | 706 | Negative | Low | 2 | 0 | 0.3 | 3.9 | 1066 | Yes |
V | 26 | 3 + 7 | 55 | F | CNS | 8 | 67.5 | 84 | 1.8 | 25.0 | >20 000† | Positive | High | 6 | 2 | 0.1 | 3.6 | 2338 | Yes |
V | 30 | 3 + 7 | 40 | M | CNS | -3 | 18.3 | 7 | 2.4 | 28.9 | >20 000† | Positive | High | 7 | 3 | 2.3 | 3.3 | 22084 | Yes |
V | 58 | 3 + 7 | 55 | M | CNS | 21 | 41.4 | 58 | 1.3 | 30.0 | >20 000† | Positive | Low | 5 | 0 | 0.7 | 3.6 | 4489 | Yes |
V | 97 | 3 + 7 | 65 | M | CNS | 35 | 109.8 | 156 | 1.1 | 27.5 | 1720 | Negative | Low | 2 | 0 | 0.5 | 4.8 | 2063 | Yes |
V | 117 | 3 + 7 | 68 | F | Musculoskeletal | 47 | 166.4 | 47 | 1.6 | 51.8 | High | 2 | 0.6 | 3.4 | 2502 | No | |||
V | 121 | 3 + 7 | 69 | M | CNS | 25 | 41.6 | 24 | 1.4 | 34.3 | High | 2 | 1.2 | 2.7 | 1135 | No | |||
V | 124 | 3 + 7 | 79 | M | Gastrointestinal | 48 | 56.2 | 40 | 1.1 | 35.8 | 2370 | Negative | Low | 4 | 1 | 0.6 | 3.0 | 754 | Yes |
V | 127 | 3 + 7 | 69 | F | CNS | 11 | 12.2 | 49 | 1.9 | 45.1 | >20 000 | Positive | High | 8 | 2 | 0.6 | 4.4 | 13927 | Yes |
V | 130 | 3 + 7 | 67 | M | CNS (retinal with symptoms) | 4 | 0.6 | 23 | 1.4 | 43.4 | 1960 | Positive | High | 5 | 2 | 1.3 | 2.9 | 988 | Yes |
V | 135 | 3 + 7 | 69 | F | CNS | -2 | 8.0 | 5 | 1.3 | 35.8 | Low | 1 | 1.0 | 3.3 | 842 | No | |||
V | 142 | 3 + 7 | 67 | F | Gastrointestinal | 6 | 23.0 | 321 | 1.2 | 33.7 | Low | 0 | 0.4 | 2.9 | 675 | Yes | |||
V | 148 | 3 + 7 | 68 | M | CNS (retinal with symptoms) | 13 | 0.8 | 105 | 1.1 | 36.8 | 2350 | Negative | Low | 2 | 0 | 0.5 | 3.8 | 342 | Yes |
V | 160 | 3 + 7 | 74 | F | CNS | 29 | 6.2 | 66 | 1.2 | 49.5 | 3830 | Negative | Low | 4 | 1 | 1.2 | 3.6 | 1359 | Yes |
Summary statistics per cohort | |||||||||||||||||||
Median | % M | % CNS | Median | Median | Median | Median | Median | Median | Median | Median | Median | % Alive | |||||||
D | 55 | 45 | 85 | 13 | 16.9 | 31 | 1.5 | 41.3 | 2472 | 0.6 | 3.4 | * | 50 | ||||||
V | 68 | 57 | 79 | 14 | 21.1 | 54 | 1.3 | 35.1 | 2155 | 0.6 | 3.5 | * | 79 |